EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

Adam S Kittai iD, Alan Skarbnik, Miguel Miranda, Alan S M Yong, Jack Roos, Robert Hettle, Sarah Palazuelos-Munoz, Vikram Shetty, Paolo Ghia

American Journal of Hematology · 2023-12 · 98 (12)

DOI: 10.1002/ajh.27110 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 09.10.2023. Verfasst von Adam S Kittai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Video Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic AgentsHumansPyrazinesProtein Kinase InhibitorsBenzamidesPiperidinesPyrazolesPyrimidines

Substanzen

Antineoplastic AgentsPyrazinesProtein Kinase InhibitorsacalabrutinibBenzamideszanubrutinibPiperidinesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Novant Health Cancer Institute, Lymphoma and Chronic Lymphocytic Leukemia Program, Charlotte, North Carolina, USA.
  • AstraZeneca, Cambridge Biomedical Campus, Cambridge, UK.
  • AstraZeneca, Gaithersburg, Maryland, USA.
  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.

ORCID-Profile: Adam S Kittai

Zitieren

APA

Kittai, A. S., Skarbnik, A., Miranda, M., Yong, A. S. M., Roos, J., Hettle, R., Palazuelos-Munoz, S., Shetty, V., & Ghia, P. (2023). A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia. American Journal of Hematology, 98(12). https://doi.org/10.1002/ajh.27110

Vancouver

Kittai AS, Skarbnik A, Miranda M, Yong ASM, Roos J, Hettle R, et al. A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia. American Journal of Hematology. 2023;98(12). doi:10.1002/ajh.27110

BibTeX
@article{Kittai2023,
  author = {Kittai, Adam S and Skarbnik, Alan and Miranda, Miguel and Yong, Alan S M and Roos, Jack and Hettle, Robert and Palazuelos-Munoz, Sarah and Shetty, Vikram and Ghia, Paolo},
  title = {A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {12},
  doi = {10.1002/ajh.27110}
}
Kostenlos starten →